1. Home
  2. SM vs RYTM Comparison

SM vs RYTM Comparison

Compare SM & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SM Energy Company

SM

SM Energy Company

HOLD

Current Price

$32.56

Market Cap

7.3B

Sector

Energy

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$86.28

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SM
RYTM
Founded
1908
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3B
6.2B
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
SM
RYTM
Price
$32.56
$86.28
Analyst Decision
Buy
Strong Buy
Analyst Count
12
14
Target Price
$34.36
$131.14
AVG Volume (30 Days)
4.0M
692.5K
Earning Date
05-06-2026
05-05-2026
Dividend Yield
2.56%
N/A
EPS Growth
N/A
28.34
EPS
N/A
N/A
Revenue
$3,154,000,000.00
N/A
Revenue This Year
$129.01
$55.34
Revenue Next Year
$6.29
$86.06
P/E Ratio
N/A
N/A
Revenue Growth
17.24
N/A
52 Week Low
$17.45
$60.71
52 Week High
$35.88
$122.20

Technical Indicators

Market Signals
Indicator
SM
RYTM
Relative Strength Index (RSI) 55.98 44.29
Support Level $25.16 $82.31
Resistance Level $33.25 $90.79
Average True Range (ATR) 1.29 3.66
MACD -0.16 -0.48
Stochastic Oscillator 45.35 7.82

Price Performance

Historical Comparison
SM
RYTM

About SM SM Energy Company

SM Energy Co is an independent energy company engaged in the acquisition, exploration, development, and production of oil, gas, and NGLs in Texas and Utah. The Company operates in the oil and gas extraction industry, focused on exploration and production activities, onshore in the United States. Its portfolio is comprised of assets in the Midland Basin of West Texas, the Maverick Basin of South Texas, and the Uinta Basin of northeastern Utah.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: